The U.S. Food and Drug Administration has “significantly and substantially failed” to fulfill its congressional mandate to protect the public health, Americans for Tax Reform (ATR) told the Reagan-Udall Foundation in a letter.
There are no shortage of battles, or even just sharp disagreements, over how food and agriculture policy should work. At times, it can get downright ugly.
Updated guidance on expanded access program clarifies that sponsors do not risk enforcement for off-label promotion if they post investigational drug expanded access policies, although that fear already may have subsided.
The U.S. Food and Drug Administration is in disarray and influenced by outside forces rather than scientific research, according to several comments submitted to the Reagan-Udall assessment of the performance of the FDA’s Center for Tobacco Products (CTP).
As the Reagan-Udall Foundation undertakes its review of the FDA’s tobacco program, a number of legal, industry and public health experts are presenting the expert panel with written and oral comments about the major issues they see with the Center for Tobacco Products’ processes and operations.
(October 28, 2022) The Reagan-Udall Foundation for the FDA is pleased to announce the launch of its Regulatory Science, Innovation, and Health Equity Fellowship Program. Increasing diversity in regulatory science serves to bring varied perspectives into the field and generate more meaningful results. By working directly on the priorities of the FDA and the Foundation, the fellowship will offer a unique opportunity for individuals to begin a career in regulatory science, while advancing health equity within the regulatory science workforce.
